Altimmune
ALT
122 hedge funds and large institutions have $640M invested in Altimmune in 2022 Q3 according to their latest regulatory filings, with 40 funds opening new positions, 39 increasing their positions, 27 reducing their positions, and 28 closing their positions.
152% more call options, than puts
Call options by funds: $49.7M | Put options by funds: $19.7M
44% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 27
43% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 28
37% more capital invested
Capital invested by funds: $467M → $640M (+$173M)
11% more funds holding
Funds holding: 110 → 122 (+12)
10% more ownership
Funds ownership: 92.33% → 102.32% (+10%)
43% less funds holding in top 10
Funds holding in top 10: 7 → 4 (-3)
Top Buyers
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$122M |
| 2 |
State Street
Boston,
Massachusetts
|
+$48.2M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
+$12.3M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$12.2M |
| 5 |
LGM
Logos Global Management
San Francisco,
California
|
+$11.1M |
Top Sellers
| 1 |
Citadel Advisors
Miami,
Florida
|
-$15M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
-$14.8M |
| 3 |
Barclays
London,
United Kingdom
|
-$13M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$11.7M |
| 5 |
Morgan Stanley
New York
|
-$11.5M |
ALT Hedge Fund Activity: Q3 2022 in Review
122 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Altimmune (ALT) for Q3 2022, worth a combined $640M — up 37% from $467M a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new ALT positions and 28 closed out — a net gain of 12 holders — while 39 added to existing stakes and 27 trimmed.
The largest buyer was Janus Henderson Group, opening a new position worth an estimated $122M. The largest seller was Citadel Advisors, cutting an estimated $15M.
- 122 institutional investors held Altimmune (ALT) as of Q3 2022, up from 110 in Q2 2022.
- Funds reported $640M of Altimmune stock for Q3 2022, up 37% quarter-over-quarter.
- 40 funds opened new Altimmune positions in Q3 2022 and 28 closed out, a net change of +12 holders.
- The largest Altimmune buyer in Q3 2022 was Janus Henderson Group, an estimated $122M added.
- The largest Altimmune seller in Q3 2022 was Citadel Advisors, an estimated $15M sold.
Based on aggregated 13F filings for Q3 2022.